Abstract To compare impact of incident diabetes on atherosclerotic cardiovascular disease (ASCVD) risk among postmenopausal women according to statin use. Prospective data from 120,499 postmenopausal women without prevalent diabetes or cardiovascular disease at baseline from the Women's Health Initiative were used. Incident diabetes was self-reported annually and defined as treatment with pills or injectable medication for diabetes. Current statin use was determined at enrollment and years 1, 3, 6, 9 and 13.5 in the three clinical trial arms, and at baseline, year 3, and 13.5 for the observational study. The primary outcome was incident ASCVD events, self-reported annually and adjudicated by blinded local and central physicians. Incident diabetes and statin use status were fitted as time-varying covariates in Cox regression models to assess ASCVD risk during an average follow-up of 13.6 years. For those not on statins at the time of diabetes diagnosis, there was a 42 % increased risk of ASCVD [hazard ratio (HR) 1.42, 95 % CI 1.28-1.58] among women with incident diabetes versus those without diabetes. Among women on statins, there was a 39 % increased risk of ASCVD (HR 1.39, 95 % CI 1.12-1.74) in women with incident diabetes versus those without diabetes. The increased ASCVD risk due to diabetes was similar between women before or after initiating statins (P = 0.89). Whether diabetes was diagnosed before or after statin use did not alter the increased risk of ASCVD associated with diabetes. Mitigating the increased incidence of diabetes in statin users could increase the ASCVD benefit-to-risk ratio of statins.
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Introduction
Presence of diabetes is a strong predictor of primary atherosclerotic cardiovascular disease (ASCVD) events [1] [2] [3] . The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines [4] and the 2015 American Diabetes Association guidelines reflect ample evidence that statin therapy decreases ASCVD events in individuals with and without diabetes [5] . However, statin use also has been shown to increase risk for newonset diabetes by 9-13 % [6] [7] [8] [9] , correlating with dose intensity [10] and with pre-existing risk status [7, 8, 11, 12] . Though adequate information exists concerning ASCVD risk in women with existing diabetes [1] , less is known about ASCVD risk among women who newly develop diabetes before or after initiation of statins. It is possible that clinical diabetes after statin initiation may be milder due to a shorter duration and earlier diagnosis or that the adverse effect of diabetes on ASCVD may be blunted by concurrent statin use. In attempt to clarify this issue, we estimated diabetes-associated risk of ASCVD events relative to statin use in an established prospective cohort of postmenopausal women.
Research design and methods

Participants
The Women's Health Initiative (WHI) recruited community dwelling postmenopausal women (N = 161,808) aged 50-79 at 40 clinical centers across the US from 1993 to 1998 with ongoing follow-up. Of these, 68,132 participants were enrolled in up to three randomized controlled clinical trials (CT) of hormones, diet, or calcium/vitamin D supplements, and 93,676 women were enrolled in the observational study (OS) [13] . The original period of follow-up ended in 2005. The analysis herein used WHI data obtained during the original follow-up as well as during an extension through September 30, 2010. Of women followed through 2005, 77 % re-enrolled in the extension and were followed through 2010. After exclusion for prevalent diabetes, baseline selfreport for CVD, and anytime use of cerivastatin, 120,499 women were included in the present analysis (Fig. 1) .
Identification of diabetes
Prevalent diabetes at baseline was defined as a self-report of ever having received a physician's diagnosis of diabetes when not pregnant. Incident diabetes status was ascertained by self-report annually; women were identified as diabetic if they reported being newly treated with medication for diabetes since their last health assessment. Self-reported diabetes has been shown to be a valid indicator for diabetes diagnosis in the WHI [14, 15] .
Assessment of statin medication use
The medication regimens of all CT participants were inventoried at baseline, year 1, 3, 6, and 9 visits, and during the extension [years 10-15 (median 13.5)]. The product name of the medication was entered into the database and matched to the corresponding item in the Master Drug Data Base (MDDB: Medi-Span, Indianapolis, IN). In the OS, medication data were collected at baseline, year 3, and during the extension. For some analyses, statin use was categorized by potency into low (fluvastatin, pravastatin, lovastatin) or high (simvastatin, atorvastatin, rosuvastatin).
Identification of ASCVD, MI, stroke, and CVD death
Primary total ASCVD was the main study endpoint in this analysis. Myocardial infarction (MI), stroke, and coronary heart disease (CHD) deaths were secondary endpoints in the present analysis. Each of these endpoints are also WHI Diabetes before statin defined as diabetes reported before reported use of statin medication, which includes the case of no reported statin use. 4 Diabetes after statin defined as diabetes reported after reported use of statin medication primary outcomes, determined by the collection of medical records, and adjudicated by blinded local and central physician review. Total ASCVD was derived from the 2013 ACC/AHA definition as nonfatal MI or CHD death, or fatal or non-fatal stroke [4] .The MI and stroke variables were both defined as fatal or non-fatal, and CVD death was classified as death from CHD or stroke. Time to first event was modeled; repeated events were not used.
Covariates
Demographic and medical health history data were selfreported at baseline. All participants completed a standardized Food Frequency Questionnaire developed for the WHI to estimate average daily nutrient intake over the three-month period prior to enrollment [16] . The Healthy Eating Index was calculated to measure overall diet quality [17] [18] [19] [20] [21] and was included in the analyses.
Total recreational physical activity energy expenditure was summarized in metabolic equivalent hours per week (MET-h/week) computed as the summed product of frequency, duration, and intensity for activities reported on a self-administered questionnaire. WHI-certified staff measured resting blood pressure by auscultation methods, and body weight, height, and waist circumference according to standardized clinical anthropometric procedures. Body mass index (BMI, kg/m 2 ) was computed from measured height and weight. Fasting concentrations for lipids, glucose, and insulin were available at baseline for a subset of approximately 20 % of the women. These measures are reported descriptively but were not used in the main analyses because of inadequate statistical power.
Statistical analysis
Statin use was summarized at each observation time (baseline, 1, 3, 6, 9 years, and during extension). For descriptive purposes, participant characteristics were summarized (means and standard deviations or counts and percentages) overall, by statin use (never, ever), and by diabetes status during the study (no, yes).
For modeling purposes, five diabetes and statin states were defined ( Fig. 2 Sensitivity analyses were conducted to probe the robustness of the results, as follows: (1) each woman was censored 3 years after last available medication data collection, (2) each woman with diabetes onset before statin use was censored at the time of any later statin use, i.e., upon entry to state (e), (3) each woman reporting no statin use subsequent to reporting statin use was censored for non-adherence, and (4) women taking a statin at baseline were excluded. The adjusted proportional hazard regression models were also refit with weights determined by Impact of incident diabetes on atherosclerotic cardiovascular disease according to statin… 749
propensity scores for baseline statin use. Variables included in the propensity score model were age, race/ethnicity, education, region, cigarette smoking, BMI, physical activity, alcohol intake, Healthy Eating Index, medical history of hypertension, systolic blood pressure, family history of cardiovascular disease, hormone therapy use, and study arms. To further understand the influence of statin use on diabetes-associated ASCVD risk, we also conducted an analysis using duration-adjusted statin data and an analysis by statin potency defined according to statin agents as low (fluvastatin, pravastatin, lovastatin) or high (simvastatin, atorvastatin, rosuvastatin). Finally we repeated the analysis using only the CT data. Analyses were performed using SAS software (version 9.3; SAS Institute Inc., Cary, NC) and/or R software (version 3.1.1; R Foundation for Statistical Computing, Vienna, Austria).
Results
Participant characteristics
Use of statin medication demonstrated a substantial upward trend from baseline (1993-1998) through extension 1 (2010) of the OS and CT arms, following similar national trends (Table 3 in ''Appendix''). Table 1 Table 4 in ''Appendix'' shows baseline characteristics of each of the five states defined by diabetes incidence and statin use. Waist circumference and BMI were higher in groups who developed diabetes but not higher in statin users than in nonusers who did not develop diabetes. Physical activity levels (MET-h/week) were lower, while family history of diabetes was higher in groups that developed diabetes. Prevalent treated hypertension was also higher in the groups that developed diabetes or used statins compared to their During an average of 13.5 years of follow-up, 2471 (2.1 %) women were diagnosed with incident diabetes after taking a statin, 8518 (7.1 %) women developed diabetes before taking a statin, and 109,510 (90.9 %) women did not develop diabetes regardless of statin status (Fig. 1) . The mean and median time to diabetes diagnosis among women without statin use at baseline (n = 10,098) was 393 (SD = 198) weeks (median: 393 weeks or 7.6 years), and in women taking statins at baseline (n = 891), it was 389 (SD = 197) weeks (median: 391 or 7.5 years). The difference in medians was not statistically significant. In multivariable-adjusted analyses, there was a 42 % increase in risk of total ASCVD for women with incident diabetes compared to women without diabetes (HR = 1.42, 95 % CI 1.28-1.58) among women who did not use statins, and a 39 % increase in risk of ASCVD in women with incident diabetes compared to those without diabetes (HR = 1.39, 95 % CI 1.12-1.74) among women who used statins. The increased risk of ASCVD associated with diabetes was similar between women with diabetes diagnosis before or after initiating statin use (P = 0.89). When we stratified the analyses by waist circumference (\85 vs. C85 cm, Table 5 in ''Appendix'') at baseline, the ASCVD risk was markedly increased for the subset with higher waist circumference in both primary exposure groups shown in Table 2 . Conversely, the subgroup with waist circumference \85 cm shows little increased risk for ASCVD. Similar hazard ratios were observed when MI, stroke, and CVD death were analyzed as separate outcomes. Weighting by propensity score for baseline statin use decreased the ASCVD hazard ratios associated with incident diabetes following statin initiation but these risks did not differ between women whose diabetes developed prior to or after statin use. The four pre-specified sensitivity analyses yielded findings that were materially comparable with the main results ( Table 2 and Table 6 in ''Appendix'').
Additional analyses were conducted attempting to account for duration of statin use (Table 7 in ''Appendix''). Although these analyses gave higher hazard ratio estimates for diabetes-associated risks of ASCVD, these risks did not differ between women whose diabetes developed prior to or after statin use. Similarly, though the ASCVD risks associated with incident diabetes in women using statins were highest for high potency statins, these risks did not differ significantly from the risks in women using low potency statins (Table 8 in ''Appendix'').
Based on the multivariable-adjusted Cox regression models derived from our study cohort, we computed absolute 10-year risks (per 1000 person-years) of ASCVD, MI, stroke, and CVD death for five hypothetical women representing the five states based on incident diabetes and statin use described previously (Fig. 3 ). All groups with incident diabetes had an increased risk of ACVD, MI, stroke, and CVD death. Groups using statins had a lower risk of ASCVD than respective counterpart groups not receiving statins, irrespective of incident diabetes status. The near equal absolute 10-year risks for ASCVD in the last two groups (i.e., d and e) reflect the equal ASCVD effects of incident diabetes regardless of its occurrance before or after initiating statin use. Much of the lower risk of ASCVD associated with statins appeared to be related to stroke risk reduction whereas a reduction in MI was not seen.
Discussion
The major finding in this large prospective observational study on community-dwelling postmenopausal women was that regardless of statin use, postmenopausal women with newonset diabetes had a significantly increased risk of ASCVD. Similar results were seen for MI, stroke, and CVD death when analyzed as separate endpoints. Whether the diabetes emerged before or after statin use, the magnitude of ASCVD risk associated with incident diabetes was considerably smaller than the previously reported 2-3 fold higher ASCVD risk associated with the diabetes status [1] [2] [3] . In those previous studies, diabetes may have been present for many years prior to the ASCVD event, while in the present study ASCVD risks were examined during a relatively short period after incident diabetes diagnosis during follow-up for ASCVD events. Importantly, when interpreting the present results, one should be mindful that our observational study analysis does not directly estimate the efficacy of statins on ASCVD risk in those with and without diabetes, for which the clinical trials are a superior source of information. Nevertheless, given the increasing prevalence of diabetes among older adults and the projected growth of this population subgroup, the present findings highlight the relevance of mitigating diabetes-related ASCVD risk seen with statin use at advanced ages.
Sex-specific risks and benefits for statins have been controversial [26, 27] . A recent large meta-analysis of clinical trials using individual data found that CVD benefits were driven by baseline risk and LDL reduction, not by sex [28] . Given the clinical trial data, 1000 women with a 10 % 10-year risk of CVD treated with statins would show an observed net *20 % reduction in CVD event rates, or 20 events (100 -80) [26, 27] . This net reduction would be higher if not for a differential increase in subsequent diabetes-associated risk of *10 % with statin use [6] . Assuming that *100 women would have developed diabetes without statins over 10 years, *10 extra cases of incident diabetes would be diagnosed after statin use. According to the current study, diabetes would confer a 40 % increase in ASCVD compared to no diabetes. Thus, among the 10 extra cases of diabetes, rather than 1 case of ASCVD over 10 years there would be 1.4 cases, i.e., an excess of 0.4 cases with statin use. Hence, the net reduction might have been 20.4 CVD events (20 ? 0.4) were it not for incident diabetes after statin use [26, 27] . When considered at the population level, this projection has considerable public health relevance as the number of older postmenopausal women increases over coming decades, paralleled by increases in diabetes prevalence and statin use. Statin-associated diabetes would be expected to blunt but not eliminate the CVD benefit observed with statin use. Our findings underscore the importance of prevention, monitoring, and detection of diabetes among post-menopausal women, and perhaps especially among those who take statin medication.
The results of the present study, while complementing findings of some published randomized trials, are also limited by the observational design and lack of detailed data for both statin use patterns and diabetes/glycemic control which complicates interpretation of these findings. We had incomplete baseline data on blood lipids and glucose measures prior to statin initiation or diabetes incidence and no data on these measures during follow-up, and we acknowledge the limitation that blood lipids, glucose and insulin measures were not included in adjusted analyses. Some misclassification of HRs estimated from PH model with additional terms for age, race/ethnicity, education, region, cigarette smoking, BMI, physical activity, alcohol intake, healthy eating index, medical history of hypertension, systolic blood pressure, family history of cardiovascular disease, hormone therapy use, and study arms Impact of incident diabetes on atherosclerotic cardiovascular disease according to statin… 755 incident diabetes in relation to statin initiation would have occurred, particularly since we considered only cases of diabetes diagnosis and did not take into account diabetes that would have been diagnosed based on blood glucose values only. Given the consistency of findings in our primary analyses and sensitivity models, it is not likely that such misclassification fully accounts for the study results. We were unable to fully account for statin duration, nor for dose and adherence. Pharmacogenomics and interactions were not assessed. However, findings from sensitivity analyses to probe the potential influence of duration and potency of statins did not differ from those for the primary analyses. Finally, we note a limitation that medication use of all CT participants were inventoried on 6 occasions at baseline, year 1, 3, 6, and 9 visits, and during the extension [years 10-15 (median 13.5)]; while in the OS, medication data were collected on only 3 occasions at baseline, year 3, and during the extension. We conducted an additional sensitivity analysis including participants in CT only; results are similar to the main results presented in the manuscript. We, therefore, believe that our results are robust. In addition, the combined sample of CT and OS increased statistical power to detect the associations especially for secondary endpoints: MI, stroke, and CVD death. Strengths of our study include the large study cohort and lengthy follow-up interval with sufficient endpoint events for the complex multivariable-adjusted and stratified analyses reported herein, and evaluation of statin use among a race-ethnically diverse cohort of postmenopausal women with a relatively wide age range at baseline. The WHI program provides ASCVD outcomes that are centrally adjudicated by a standardized protocol. The use of propensity score analyses and several additional sensitivity and stratified analyses allowed for evaluation of potential confounders and effect modifiers in a comprehensive manner within the constraints of the observational study design and available data.
In conclusion, a similar increase in risk for primary ASCVD events associated with diabetes was seen in older postmenopausal women, regardless of whether incident diabetes diagnosis occurred before or after initiation of statin use. Much of the incident diabetes seems to occur in those with markers of metabolic syndrome at baseline. These findings suggest that mitigating development of diabetes has an important role in the scope of primary ASCVD prevention among older postmenopausal women. 
Appendix
See Tables 3, 4 , 5, 6, 7 and 8. Values are expressed as N(%) unless otherwise noted a Number adds up to more than total study population because women can change states over the follow-up period There is no statistical difference between these diabetes groups and risk of ASCVD, after adjustment for multiple comparisons alpha level = 0.017 c HRs estimated from PH model with additional terms for age, race/ethnicity, education, region, cigarette smoking, BMI, physical activity, alcohol intake, healthy eating index, medical history of hypertension, systolic blood pressure, family history of cardiovascular disease, hormone therapy use, and study arms Statin use and diabetes status using revised data to include duration of statin use reported up to 2 years before medication inventory and censored 3.5 years after previous medication inventory, and setting diabetes report back 6 months from form submission a P value for test of no difference between effect of diabetes diagnosis before statin (if any) and the effect of diabetes diagnosis after statin b HRs estimated from PH model including factors for statin use, diabetes diagnosis before statins, diabetes diagnosis after statins c HRs estimated from PH model with additional terms for age, race/ethnicity, education, region, cigarette smoking, BMI, physical activity, alcohol intake, healthy eating index, medical history of hypertension, systolic blood pressure, family history of cardiovascular disease, hormone therapy use, and study arms
